vs
DOMO, INC.（DOMO）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
DOMO, INC.的季度营收约是MESA LABORATORIES INC的1.2倍（$79.4M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -13.1%，领先18.7%），MESA LABORATORIES INC同比增速更快（3.6% vs -0.5%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $1.1M），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs -0.5%）
Domo股份有限公司是总部设在美国犹他州美国福克的美国云软件企业，主营人工智能、商业智能与数据可视化业务，属于SaaS（软件即服务）企业，核心产品可帮助企业各层级决策者在极少IT介入的情况下，实时获取业务数据，支撑决策开展。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
DOMO vs MLAB — 直观对比
营收规模更大
DOMO
是对方的1.2倍
$65.1M
营收增速更快
MLAB
高出4.1%
-0.5%
净利率更高
MLAB
高出18.7%
-13.1%
自由现金流更多
MLAB
多$16.9M
$1.1M
两年增速更快
MLAB
近两年复合增速
-0.5%
损益表 — Q3 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $79.4M | $65.1M |
| 净利润 | $-10.4M | $3.6M |
| 毛利率 | 74.2% | 64.2% |
| 营业利润率 | -8.7% | 12.2% |
| 净利率 | -13.1% | 5.6% |
| 营收同比 | -0.5% | 3.6% |
| 净利润同比 | 44.6% | 316.6% |
| 每股收益（稀释后） | $-0.25 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DOMOMLAB
| Q4 25 | $79.4M | $65.1M | ||
| Q3 25 | $79.7M | $60.7M | ||
| Q2 25 | $80.1M | $59.5M | ||
| Q1 25 | $78.8M | $62.1M | ||
| Q4 24 | $79.8M | $62.8M | ||
| Q3 24 | $78.4M | $57.8M | ||
| Q2 24 | $80.1M | $58.2M | ||
| Q1 24 | $80.2M | $58.9M |
净利润DOMOMLAB
| Q4 25 | $-10.4M | $3.6M | ||
| Q3 25 | $-22.9M | $2.5M | ||
| Q2 25 | $-18.1M | $4.7M | ||
| Q1 25 | $-17.7M | $-7.1M | ||
| Q4 24 | $-18.8M | $-1.7M | ||
| Q3 24 | $-19.5M | $3.4M | ||
| Q2 24 | $-26.0M | $3.4M | ||
| Q1 24 | $-18.7M | $-254.6M |
毛利率DOMOMLAB
| Q4 25 | 74.2% | 64.2% | ||
| Q3 25 | 74.8% | 61.5% | ||
| Q2 25 | 74.2% | 62.0% | ||
| Q1 25 | 74.4% | 61.8% | ||
| Q4 24 | 75.0% | 63.3% | ||
| Q3 24 | 74.3% | 61.3% | ||
| Q2 24 | 74.1% | 64.0% | ||
| Q1 24 | 76.3% | 62.1% |
营业利润率DOMOMLAB
| Q4 25 | -8.7% | 12.2% | ||
| Q3 25 | -9.1% | 7.8% | ||
| Q2 25 | -17.9% | 5.1% | ||
| Q1 25 | -15.6% | 2.4% | ||
| Q4 24 | -13.9% | 9.2% | ||
| Q3 24 | -18.5% | 6.1% | ||
| Q2 24 | -26.8% | 9.6% | ||
| Q1 24 | -16.6% | -460.6% |
净利率DOMOMLAB
| Q4 25 | -13.1% | 5.6% | ||
| Q3 25 | -28.8% | 4.1% | ||
| Q2 25 | -22.5% | 8.0% | ||
| Q1 25 | -22.4% | -11.4% | ||
| Q4 24 | -23.5% | -2.7% | ||
| Q3 24 | -24.9% | 5.9% | ||
| Q2 24 | -32.5% | 5.8% | ||
| Q1 24 | -23.3% | -432.2% |
每股收益（稀释后）DOMOMLAB
| Q4 25 | $-0.25 | $0.65 | ||
| Q3 25 | $-0.56 | $0.45 | ||
| Q2 25 | $-0.45 | $0.85 | ||
| Q1 25 | $-0.45 | $-1.30 | ||
| Q4 24 | $-0.48 | $-0.31 | ||
| Q3 24 | $-0.51 | $0.63 | ||
| Q2 24 | $-0.69 | $0.62 | ||
| Q1 24 | $-0.51 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $29.0M |
| 总债务越低越好 | $124.2M | $68.4M |
| 股东权益账面价值 | $-191.9M | $186.7M |
| 总资产 | $201.6M | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资DOMOMLAB
| Q4 25 | — | $29.0M | ||
| Q3 25 | — | $20.4M | ||
| Q2 25 | $47.2M | $21.3M | ||
| Q1 25 | $45.3M | $27.3M | ||
| Q4 24 | — | $27.3M | ||
| Q3 24 | — | $24.3M | ||
| Q2 24 | $61.2M | $28.5M | ||
| Q1 24 | $60.9M | $28.2M |
总债务DOMOMLAB
| Q4 25 | $124.2M | $68.4M | ||
| Q3 25 | $121.9M | $69.4M | ||
| Q2 25 | $119.7M | $70.3M | ||
| Q1 25 | $117.7M | $71.3M | ||
| Q4 24 | $115.6M | $72.2M | ||
| Q3 24 | $115.2M | $73.1M | ||
| Q2 24 | $114.1M | $74.1M | ||
| Q1 24 | $113.5M | — |
股东权益DOMOMLAB
| Q4 25 | $-191.9M | $186.7M | ||
| Q3 25 | $-191.5M | $178.5M | ||
| Q2 25 | $-178.7M | $172.5M | ||
| Q1 25 | $-177.2M | $159.8M | ||
| Q4 24 | $-171.2M | $155.2M | ||
| Q3 24 | $-166.4M | $161.5M | ||
| Q2 24 | $-163.5M | $150.7M | ||
| Q1 24 | $-153.5M | $145.4M |
总资产DOMOMLAB
| Q4 25 | $201.6M | $434.8M | ||
| Q3 25 | $195.7M | $430.4M | ||
| Q2 25 | $189.7M | $435.7M | ||
| Q1 25 | $214.3M | $433.3M | ||
| Q4 24 | $190.2M | $433.3M | ||
| Q3 24 | $197.8M | $454.1M | ||
| Q2 24 | $204.4M | $440.4M | ||
| Q1 24 | $225.7M | $446.8M |
负债/权益比DOMOMLAB
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.4M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | $1.1M | $18.0M |
| 自由现金流率自由现金流/营收 | 1.4% | 27.7% |
| 资本支出强度资本支出/营收 | 2.9% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | $9.9M | $37.9M |
8季度趋势，按日历期对齐
经营现金流DOMOMLAB
| Q4 25 | $3.4M | $18.8M | ||
| Q3 25 | $3.4M | $8.2M | ||
| Q2 25 | $4.0M | $1.9M | ||
| Q1 25 | $8.9M | $12.7M | ||
| Q4 24 | $-13.7M | $18.1M | ||
| Q3 24 | $-6.2M | $5.3M | ||
| Q2 24 | $1.9M | $10.7M | ||
| Q1 24 | $5.4M | $12.9M |
自由现金流DOMOMLAB
| Q4 25 | $1.1M | $18.0M | ||
| Q3 25 | $1.0M | $7.1M | ||
| Q2 25 | $1.0M | $884.0K | ||
| Q1 25 | $6.7M | $11.9M | ||
| Q4 24 | $-16.2M | $17.3M | ||
| Q3 24 | $-8.4M | $3.5M | ||
| Q2 24 | $-625.0K | $9.9M | ||
| Q1 24 | $2.9M | $12.3M |
自由现金流率DOMOMLAB
| Q4 25 | 1.4% | 27.7% | ||
| Q3 25 | 1.3% | 11.7% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 8.5% | 19.2% | ||
| Q4 24 | -20.3% | 27.6% | ||
| Q3 24 | -10.7% | 6.0% | ||
| Q2 24 | -0.8% | 16.9% | ||
| Q1 24 | 3.6% | 21.0% |
资本支出强度DOMOMLAB
| Q4 25 | 2.9% | 1.1% | ||
| Q3 25 | 2.9% | 1.8% | ||
| Q2 25 | 3.7% | 1.7% | ||
| Q1 25 | 2.8% | 1.2% | ||
| Q4 24 | 3.2% | 1.3% | ||
| Q3 24 | 2.8% | 3.1% | ||
| Q2 24 | 3.2% | 1.5% | ||
| Q1 24 | 3.1% | 0.9% |
现金转化率DOMOMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | — | 3.32× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
